, Market Snapshots, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological autoimmune disorder where myelin, an essential part of the nervous system is being attacked by the body's immune system. It is a medical condition where the body's immune system fails to differentiate between own cells and foreign cells and starts attacking its healthy cells. As per the analysis of Market Research Future (MRFR), the global chronic inflammatory demyelinating polyneuropathy market is aiming for a CAGR of 6.2% and is due to reach USD 3907.17 Mn by the end of the forecast period of 2018-2023. The global chronic inflammatory demyelinating polyneuropathy market stood at USD 2723.42 Mn in 2017. There has been a spiraling rise in the prevalence of autoimmune disorders in the recent past which offers scope for the growth of the global chronic inflammatory demyelinating polyneuropathy disease market. Patients suffering from autoimmune disorders are more likely to suffer from the disease. Growing incidences of CIDP has evoked major concern within the medical sector, especially in the developed countries. Various public, as well as private organizations, have undertaken initiatives for R&D activities which has yielded positive outcomes in the CIDP space. Noteworthy results have been achieved through rigorous R&D efforts and clinical trials. Various new drugs have been launched into the market after recent FDA approvals which also boosts the growth of the global chronic inflammatory demyelinating polyneuropathy market. Other factors encouraging the growth of the market include surging awareness about the disease and government endeavors regarding the same. On the downside, the high cost of Intravenous immunoglobulin treatment and the side effects accompanied with its administration such as hypotension, nausea, lower back pain, flushing, chills, wheezing, etc. remain hindrance to the growth of the market. Meanwhile, high unmet need for advanced treatment options for the disease is

Market Snapshots

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological autoimmune disorder where myelin, an essential part of the nervous system is being attacked by the body's immune system. It is a medical condition where the body's immune system fails to differentiate between own cells and foreign cells and starts attacking its healthy cells. As per the analysis of Market Research Future (MRFR), the global chronic inflammatory demyelinating polyneuropathy market is aiming for a CAGR of 6.2% and is due to reach USD 3907.17 Mn by the end of the forecast period of 2018-2023. The global chronic inflammatory demyelinating polyneuropathy market stood at USD 2723.42 Mn in 2017. There has been a spiraling rise in the prevalence of autoimmune disorders in the recent past which offers scope for the growth of the global chronic inflammatory demyelinating polyneuropathy disease market. Patients suffering from autoimmune disorders are more likely to suffer from the disease. Growing incidences of CIDP has evoked major concern within the medical sector, especially in the developed countries. Various public, as well as private organizations, have undertaken initiatives for R&D activities which has yielded positive outcomes in the CIDP space. Noteworthy results have been achieved through rigorous R&D efforts and clinical trials. Various new drugs have been launched into the market after recent FDA approvals which also boosts the growth of the global chronic inflammatory demyelinating polyneuropathy market. Other factors encouraging the growth of the market include surging awareness about the disease and government endeavors regarding the same. On the downside, the high cost of Intravenous immunoglobulin treatment and the side effects accompanied with its administration such as hypotension, nausea, lower back pain, flushing, chills, wheezing, etc. remain hindrance to the growth of the market. Meanwhile, high unmet need for advanced treatment options for the disease is likely to bring to view new opportunities for market players over the forecast period.



Players Covered

Bio Products Laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, CSL Behring,Teijin Pharma Limited, Pfizer, Inc. are the key players in the global chronic inflammatory demyelinating polyneuropathy market.

Segmental Analysis

By Treatment & Diagnosis



Treatment Intravenous Immunoglobulin



Corticosteroids



Plasmapheresis (plasma exchange)



Physiotherapy



Others



Diagnosis



Electrodiagnostic Testing



Nerve Conduction



EMG



Spinal Fluid Analysis



Others



By Route of Administration



Intravenous



Oral



Others



By End User



Hospitals



Specialty Neurological Clinics



Research & Academic Laboratories



Others



Report Overview

This MRFR report provides a forward-looking perspective on the different factors influencing the growth of the Global Chronic Inflammatory Demyelinating Polyneuropathy Market. Drivers, restraints, opportunities, challenges and other factors are discussed in detail to promote a deeper understanding of the market dynamics. The report covers a detailed profile of key players, their market share, geographical presence, strategies adopted by them and changing competition dynamics. Various treatment methods such as intravenous immunoglobulin, corticosteroids, plasmapheresis, physiotherapy, and others are covered. The diverse end user segments included in the report are hospitals, specialty neurological clinics, research & academic laboratories, and others. The report analyzes the key competencies of key players and provides insights into the strategies adopted by them to gain an edge over the market. Geographical presence of each player, their market share, country-level analysis and revenue forecast for each segment has also been provided in the report.



Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, by Region



Americas



US

Canada









North America





Latin America





Europe



Germany

France

Italy

Spain

UK

Rest of Western Europe









Western Europe





Eastern Europe





Asia-Pacific





Japan





China





India





Australia





South Korea





Rest of Asia-Pacific





The Middle East & Africa





Middle East





Africa





Research Methodology

MRFR provides thoroughly studied market reports by combining the right mix of primary and secondary research methods, to aid clients to achieve their business goals. MRFR's research modules are designed with a specialized approach to meet industry-specific standards. A skilled team of analyst employs primary research techniques such as questionnaires, interviews, and personal interaction with key level market participants to collect valuable information about the market. Data collected from secondary sources such as white papers, annual reports, company websites, paid databases are combined with primary data to provide high-quality, accurate, and unbiased results.



Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disorder that causes the immune system of the body to attack the myelin, which is an important part of the nervous system. Chronic inflammatory demyelinating polyneuropathy is a growing market as per the analysis of Market Research Future (MRFR). According to the report, the global chronic inflammatory demyelinating polyneuropathy market has been projected to reach the USD 3907.17 million marks at a CAGR of 6.2% over the forecast period of 2017-2023.

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market has experienced witnessed substantial growth over the last few years due to the demand from the medical sector and growing awareness about the hazard it can be.

Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), increasing research and development (R&D) related to plasma-derived medicines, and the rising prevalence of autoimmune diseases. The market for CIDP can grow as it enables advanced treatment for this disorder and makes it more accessible. However, side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment and the high cost of IVIG treatment can hinder market growth.

The Global Chronic Inflammatory Demyelinating Polyneuropathy Market has been segmented on the basis of end users, route of administration, treatment & diagnosis, and lastly region.

Based on end users, this market has been segmented into hospitals, research & academic laboratories, specialty neurological clinics, and others. Hospitals segment is likely to witness the highest growth at 6.28% CAGR during the forecast period.

Regarding the route of administration, the market has been segmented into intravenous, oral, and others. The intravenous segment is expected to witness the highest growth at 6.46% CAGR during the forecast period.

On the basis of treatment & diagnosis, the market has been segmented into the market has been segmented into diagnosis and treatment. Treatment segment is expected to witness the highest growth at 6.32% CAGR during the forecast period.

Regional Analysis

The regional segmentation of the Chronic inflammatory demyelinating polyneuropathy market covers regions such as The Americas (North America & South America), Europe, Asia Pacific, and the Middle East & Africa (MEA). The Asia Pacific is anticipated to be the fastest growing regional market. It has been anticipated to witness huge growth at 7.03% CAGR due to rapid urbanization, steadily rising technological advancement, and improving medical facilities. The pivotal country-specific markets in this region are Australia, China, India, Japan, and South Korea, followed by the remaining countries of the Asia Pacific region. China is the fastest growing market in this region, growing at 7.84% CAGR. Its worth by the end of forecast period has been estimated to be USD 192.42 million.

The Americas is the largest regional market with 52% of global share. In 2017, its value was USD 1415.96 million. During the forecast period, it may grow at a 5.90% CAGR with the worth of USD 1997.30 million. In this region, North America is a bigger market than South America due to the already established medical sector, advanced technology, and more awareness regarding CIDP. During the forecast period, the North American market is likely to witness faster growth compared to the South American market with 6.23% CAGR, and its worth is expected to be USD 1667.62 million. USA and Canada are the significant country-specific markets in this region. In this region, advanced medical facilities and higher purchasing power of patients and potential patients contribute to the market growth. The USA is the largest country-specific market in this region which is expected to grow at 6.48% CAGR by the end of the forecast period, and its worth has been estimated at USD 1352.99 million.

Europe is the second largest regional market. The pivotal country-specific markets in this region are Germany, France, Italy, Russia, Spain, and the UK, followed by the remaining countries of Western Europe and then Eastern Europe. Major factor aiding the market growth in this region is technological advancement second only to North America and advanced medical facilities. Due to both of these factors, Western Europe is a bigger market than Eastern Europe. The market growth for Europe is expected to register growth at 6.47% CAGR during the forecast period. Italy is likely to witness the highest growth in Europe at 7.75% CAGR during the forecast period.

In the MEA region, the market is limited to due to lack of education, lack of awareness, lack of advanced medical facilities, and limited availability of advanced technology. Overall market growth during the forecast period has been estimated to be The Middle East market is bigger than the African market. During the forecast period, the Middle East market is expected to grow at 5.08% CAGR.

Competitive Tracking

Baxter, Bio Products Laboratory Ltd., CSL Behring, Grifols, Kedrion S.P.A, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Octapharma, Pfizer Inc, Shire, and Teijin Pharma Limited.